Your odds of surviving kidney cancer swing dramatically from over 90% to under 16%, a stark divide that hinges largely on one critical factor explored in the statistics ahead.
Key Takeaways
- The 5-year relative survival rate for kidney and renal pelvis cancer overall is 76.4% for patients diagnosed between 2013-2019
- The 10-year relative survival rate for kidney cancer is approximately 57% based on SEER data from 2012-2018
- In the US, the 5-year survival rate for kidney cancer improved from 64% in the 1970s to 76% in recent years
- SEER data shows 5-year survival for localized kidney cancer at 92.9% (2013-2019)
- 5-year survival for regional stage kidney cancer is 71.4% per SEER 2013-2019
- Distant metastatic kidney cancer has 5-year survival of 15.1% (SEER 2013-2019)
- For patients under 45, localized kidney cancer 5-year survival is 98.3% (SEER)
- Males have 5-year kidney cancer survival of 75.2% vs 77.9% for females (SEER 2013-2019)
- Black patients 5-year survival 73.6% vs 77.1% for White (SEER)
- Nephrectomy patients have 5-year survival of 85% for early stage
- Partial nephrectomy 5-year survival 95.5% vs radical 93.6% for T1a
- Sunitinib first-line mRCC median OS 26.4 months
- High Fuhrman grade associated with 20% lower 5-year survival
- Sarcomatoid differentiation reduces median OS to 10 months
- Elevated LDH >1.5x ULN predicts median OS 4 months in mRCC
Kidney cancer survival has significantly improved, especially when diagnosed at an early stage.
Demographic Survival Variations
1For patients under 45, localized kidney cancer 5-year survival is 98.3% (SEER)
Verified2Males have 5-year kidney cancer survival of 75.2% vs 77.9% for females (SEER 2013-2019)
Verified3Black patients 5-year survival 73.6% vs 77.1% for White (SEER)
Verified4Age 65-74 group has 5-year survival of 75.8% for kidney cancer
Directional5Women under 65 have 84% 5-year survival for localized RCC
Single source6Hispanic patients 5-year survival 78.9% (SEER)
Verified7Elderly >80 years 5-year survival drops to 47.2%
Verified8Asian/Pacific Islander 5-year survival 80.7% (SEER)
Verified9Rural residents have 2% lower 5-year survival than urban
Directional10Smokers have 15% lower 5-year survival for RCC vs non-smokers
Single source11Age <50 localized stage 5-year survival 97%
Verified12Female gender advantage 5-year survival +2.7% (SEER)
Verified13American Indian 5-year survival 72.1% (SEER)
Verified1445-64 age group 5-year survival 82.5%
Directional15Obese patients BMI>30 have 10% worse survival
Single source16Socioeconomic low quintile survival 5% lower
Verified17Male smokers 5-year survival 70% vs 80% non-smokers
Verified18Urban vs rural survival gap 3.2% at 5 years
Verified19Comorbid diabetes reduces OS by 25%
Directional20Hypertension comorbidity 5-year survival 74%
Single sourceDemographic Survival Variations Interpretation
These statistics reveal a clear, sobering hierarchy: while youth and early detection offer near-certain victory, the battle against kidney cancer is disproportionately harder for the elderly, smokers, those with comorbidities, and patients facing systemic disadvantages rooted in race, income, and geography.
Overall Survival Statistics
1The 5-year relative survival rate for kidney and renal pelvis cancer overall is 76.4% for patients diagnosed between 2013-2019
Verified2The 10-year relative survival rate for kidney cancer is approximately 57% based on SEER data from 2012-2018
Verified3In the US, the 5-year survival rate for kidney cancer improved from 64% in the 1970s to 76% in recent years
Verified4European age-standardized 5-year survival for kidney cancer is 60.3% (2010-2014 data)
Directional5In England, the 5-year net survival for kidney cancer is 56.6% for patients diagnosed 2016-2020
Single source6Australian 5-year relative survival for kidney cancer diagnosed 2014-2018 is 72%
Verified7Japanese 5-year survival rate for renal cell carcinoma is 81.9% (2006-2008 cohort)
Verified8In China, 5-year overall survival for RCC is 38.7% from a multi-center study 2005-2014
Verified9Canadian 5-year net survival for kidney cancer 2014-2018 is 68%
Directional10Global 5-year survival for kidney cancer varies from 36% in low-income to 74% in high-income countries (CONCORD-3)
Single source11Clear cell subtype 5-year survival 77% vs 62% papillary (SEER)
Verified125-year survival for chromophobe RCC is 89%
Verified13Collecting duct carcinoma 5-year survival <20%
Verified14Unclassified RCC 5-year survival 68%
Directional15Median OS for advanced non-clear cell RCC 24.8 months with cabozantinib
Single source165-year survival in MSKCC favorable risk mRCC 32%
VerifiedOverall Survival Statistics Interpretation
While the odds of surviving kidney cancer have improved dramatically, your specific prognosis is a complex cocktail shaken with your tumor's personality, your country's healthcare system, and a sobering dash of global inequality.
Risk Factor and Prognostic Survival Stats
1High Fuhrman grade associated with 20% lower 5-year survival
Verified2Sarcomatoid differentiation reduces median OS to 10 months
Verified3Elevated LDH >1.5x ULN predicts median OS 4 months in mRCC
Verified4IMDC poor risk mRCC median OS 8.8 months
Directional5Neutrophil-lymphocyte ratio >4 linked to 50% higher mortality risk
Single source6Tumor size >7cm reduces 5-year recurrence-free survival to 60%
Verified7Positive surgical margins decrease 5-year survival by 15%
Verified8ECOG PS >=2 halves median OS in advanced RCC
Verified9Low hemoglobin prognosticates poorer survival in MSKCC model
Directional10Lymphovascular invasion predicts 40% recurrence risk at 5 years
Single source11Rhabdoid features median OS 7 months
Verified12Hypercalcemia in mRCC median OS 4.6 months
Verified13IMDC intermediate risk median OS 20.6 months
Verified14Platelet-lymphocyte ratio >193 worse OS HR 2.1
Directional15Necrosis >10% tumor volume 5-year RFS 70%
Single source16Perinephric fat invasion 5-year CSS 75%
Verified17Anemia <LLN OS HR 1.8 in advanced disease
Verified18Time from diagnosis to treatment >60 days worse survival
Verified19MSKCC favorable risk 5-year survival 60%
DirectionalRisk Factor and Prognostic Survival Stats Interpretation
This grim roll call of tumor treachery, from rebellious cells to hijacked blood labs, paints a stark portrait of kidney cancer as a formidable foe that weaponizes everything from its own architecture to the body's distress signals to undermine survival.
Stage-Specific Survival Rates
1SEER data shows 5-year survival for localized kidney cancer at 92.9% (2013-2019)
Verified25-year survival for regional stage kidney cancer is 71.4% per SEER 2013-2019
Verified3Distant metastatic kidney cancer has 5-year survival of 15.1% (SEER 2013-2019)
Verified4Stage I RCC 5-year cancer-specific survival is 96.4% post-surgery
Directional5Stage II kidney cancer 5-year survival is 87% according to ACS
Single source6Stage III RCC 5-year overall survival is 64% in surgical cohorts
Verified7Stage IV metastatic RCC median overall survival is 18 months with modern therapies
Verified8T1a tumors have 5-year survival >98%
Verified9T3 RCC stage 5-year survival is 53%
Directional10Localized disease (T1-2N0M0) 10-year survival is 81.5%
Single source11Stage I-II 5-year survival 93% per ACS data
Verified12Stage III 5-year survival 60% (ACS)
Verified13Stage IV 5-year survival 12% (ACS)
Verified14pT1N0M0 10-year CSS 94.2%
Directional15N1 disease 5-year survival 45%
Single source16M1 at diagnosis median OS 14 months pre-immunotherapy era
Verified17T1b 5-year RFS 85%
Verified18Lymph node positive stage 5-year OS 40%
Verified19Oligometastatic (≤3 sites) 5-year survival 30%
DirectionalStage-Specific Survival Rates Interpretation
The data paints a brutally clear picture: kidney cancer is often curable if caught early and confined, but becomes a fierce and formidable adversary once it gains ground, with survival odds plummeting as it advances.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3CONCANCconcanc.euVisit source
- Reference 4CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 5AIHWaihw.gov.auVisit source
- Reference 6PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 7CANCERcancer.caVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source